Aasly et al (23)23 Aasly JO, Johansen KK, Bronstad G, Waro BJ, Majbour NK, Varghese S, et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Frontiers Aging Neurosci[Internet]. 2014[cited 2017 May 23];6:248. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174885/pdf/fnagi-06-00248.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2014) |
|
|
|
α-synuclein; o- α- synuclein; t-α- synuclein; LRRK2 |
α-synuclein: 74.00 o- α- synuclein: 79.00 t-α- synuclein; 64.00 LRRK2:66.00 |
α-synuclein: 65.00 o- α- synuclein: 73.00 t-α- synuclein; 53.00 LRRK2:63.00 |
α-synuclein:83.00 o- α- synuclein: 77.00 t-α- synuclein; 81.00 LRRK2:74.00 |
Aguiar et al (13)13 Aguiar PMC, Severino P. Biomarkers in Parkinson Disease: global gene expression analysis in peripheral blood from patients with and without mutations in PARK2 and PARK8. Einstein[Internet]. 2010[cited 2017 May 23];8(3 Pt 1):291-7. Available from: http://apps.einstein.br/revista/arquivos/PDF/1674-Einsteinv8n3_pg291-7_eng.pdf
http://apps.einstein.br/revista/arquivos...
(2010) |
15 |
10 |
5 |
PARK2 ou PARK8 |
|
|
|
Boll et al (22)22 Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF: a different marker profile in four neurodegenerative diseases. Neurochem Res[Internet]. 2008[cited 2017 May 28];33(9):1717-23. Available from: https://link.springer.com/article/10.1007%2Fs11064-008-9610-3
https://link.springer.com/article/10.100...
(2008) |
102 |
22 |
80 |
Cu/Zn-SOD; Lipid peroxidation assay; NOx; Celuloplasmin ferroxidase |
|
|
|
Cao et al (16)16 Cao XY, Lu JM, Zhao ZQ, Li MC, Lu T, An XS, Xue LJ. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett[Internet]. 2017[cited 2017 May 23];644:94-9. Available from: http://europepmc.org/abstract/med/28223160
http://europepmc.org/abstract/med/282231...
(2017) |
149 |
109 |
40 |
miR-24, mi R-30a-3p, mi R-30e-3p, miR-195, miR-223*, mi R-324-3p, mi R-331-5p, mi R-338-3p, miR-505, miR-626, miR- 15b, miR-16-2-3p, miR-19a, miR-19b, miR-29a, miR-29c, mi R-30c, miR-148b, miR-181a, miR-185, miR-221, mi R-339-5p, miR-450b-3p, and miR-1294 |
miR-19b, 0.75, (0.67–0.82); miR-24, 0,90 (0.85–0.94), and miR-195, 0.69 (0.61–0.77), miR-19b, miR-24 and miR-195. 0.94 (0.91–0.98). |
miR-195, 82.6 miR-19b, 68.8 miR-24, 81.7 miR-19b, miR-24 and miR-195: 85.3. |
miR-195, 55.0%, ; miR-19b, 77.5%; miR-24, 81.7%, miR-19b, miR-24 and miR-195: 90% |
Ding et al (5)5 Ding H, Huang Z, Chen M, Wang C, Chen X, Chen J, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord[Internet]. 2016[cited 2017 May 23];22:68-73. Available from: http://www.prd-journal.com/article/S1353-8020 (15)30038-9/pdf
http://www.prd-journal.com/article/S1353...
(2016) |
197 |
106 |
91 |
hsa-miR-195 hsa-miR-15b hsa-miR-221 hsa-miR-181a hsa-miR-185 |
hsa-miR-195: 73.30 hsa-miR-15b: 89.70 hsa-miR-221: 85.40 hsa-miR-181a: 82.20 hsa-miR-185: 82.00 |
hsa-miR-195: 68.90 hsa-miR-15b: 76.90 hsa-miR-221: 75.80 hsa-miR-181a: 70.30 hsa-miR-185: 70.00 |
hsa-miR 195:75.80 hsa-miR 15b:86.80 hsa-miR 221:85.80 hsamiR181a:84.00 hsa-miR 185:83.00 |
Foulds et al (27)27 Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. Faseb J[Internet]. 2011[cited 2017 May 23];25(12):4127-37. Available from: http://www.fasebj.org/content/25/12/4127.long
http://www.fasebj.org/content/25/12/4127...
(2011) |
62 |
32 |
30 |
phospho- α-synuclein; α-synuclein; oligo- α-synuclein; oligo- phospho- α-synuclein |
oligo- phospho- α-synuclein: 62 |
___
|
___
|
Foulds et al (2)2 Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, et al. A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep[Internet]. 2013[cited 2017 May 28];3:2540. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756331/pdf/srep02540.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2013) |
280 |
189 |
91 |
phosphorylated α-synuclein;α-synuclein; |
phosphorylated α-synuclein: 71.70 α-synuclein:55.80 |
___ |
___ |
Goldknopf et al (28)28 Goldknopf IL, Bryson JK, Strelets I, Quintero S, Sheta EA, Mosqueda M, et al. Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun[Internet]. 2009[cited 2017 May 28];389(2):321-7. Available from: http://www.sciencedirect.com/science/article/pii/S0006291X09017392?via%3Dihub
http://www.sciencedirect.com/science/art...
(2009) |
226 |
29 + 62 |
57 + 78 |
A. 57 Biomarkers; B. 21 Biomarkers |
|
A. 57 Biomarkers: 96.40 B. 21 Biomarkers: 92.90 |
A. 57 Biomarkers: 93.30 B. 21 Biomarkers:93.30 |
Gorostidi et al (25)25 Gorostidi A, Bergareche A, Ruiz-Martinez J, Marti-Masso JF, Cruz M, Varghese S, et al. α-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One[Internet]. 2012[cited 2017 May 28];7(12):e52312. Available from: http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0052312&type=printable
http://journals.plos.org/plosone/article...
(2012) |
275 |
166 |
109 |
LRRK2; α-synuclein; iPD |
|
___
|
___
|
Grünblatt et al (17)17 Grunblatt E, Zehetmayer S, Jacob CP, Muller T, Jost WH, Riederer P. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm[Internet]. 2010[cited 2017 May 28];117(12):1387-93. Available from: https://link.springer.com/article/10.1007%2Fs00702-010-0509-1
https://link.springer.com/article/10.100...
(2010) |
139 |
105 |
34 |
PSMA2; LAMB2; ALDH1A1; HIST1H3E |
PSMA2:87.20 LAMB2: 82.50 ALDH1A1:75.80 HIST1H3E: 72.00 |
|
|
Gui et al (14)14 Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget[Internet]. 2015[cited 2017 May 28];6(35):37043-53. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741914/pdf/oncotarget-06-37043.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2015) |
74 |
47 |
27 |
miR-1; miR-153; miR-409-3p; miR-19b-3p; miR-10ª-5p; miR153/mir-409-3p) |
miR-1: 92.00 miR-153: 78.00 miR-409-3p: 97.00 miR-19b-3p: 70.50 miR-10a-5p: 90.00 |
miR-1: 94.00 miR-153: 93.00 miR-409-3p: 90.00 miR-19b-3p: 94.00 miR-10a-5p: 95.00 |
miR-1: 94.00 miR-153: 93.00 miR-409-3p: 90.00 miR-19b-3p: 94.00 miR-10a-5p: 95.00 |
Han et al (29)29 Han M, Nagele E, DeMarshall C, Acharya N, Nagele R. Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One[Internet]. 2012[cited 2017 May 23];7(2):e32383. Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0032383
http://journals.plos.org/plosone/article...
(2012) |
69 |
29 |
40 |
Autoantibody (10): NM_001544.2 NM_024754.2 BC051695.1 PHR5001 NM_006790.1 NM_032855.1 BC005858.1
NM_003141.2 BC094687.1 BC027617.1 |
|
93.10 |
100 |
Kang et al (12)12 Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol[Internet]. 2013[cited 2015 Jul 23];70(10):1277-87. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034348/pdf/nihms573438.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2013) |
102 |
63 |
39 |
Aβ1–42; Tau [T-tau]; [P-tau181]; α-synuclein |
|
___
|
___
|
Karlsson et al (24)24 Karlsson MK, Sharma P, Aasly J, Toft M, Skogar O, Saebo S, et al. Found in transcription: accurate Parkinson's disease classification in peripheral blood. J Parkinsons Dis[Internet]. 2013[cited 2017 May 28];3(1):19-29. Available from: https://content.iospress.com/download/journal-of-parkinsons-disease/jpd120159?id=journal-of-parkinsons-disease%2Fjpd120159
https://content.iospress.com/download/jo...
(2013) |
154 |
79 |
75 |
α-synuclein (SNCA/PARK1/4); (PRKN/PARK2); L1 (UCHL-1/PARK5); (PINK1/PARK6); DJ-1 (DJ1/PARK7); (LRRK2/PARK8); (VPS35/PARK17); (EIF4G1/PARK18) |
|
|
|
Khoo et al (30)30 Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, et al. Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis[Internet];2012[cited 2017 May 23];2(4):321-31. Available from: https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd012144
https://content.iospress.com/articles/jo...
(2012) |
64 |
32 |
32 |
miR-626; miR-505; miR-222; k-TSP1; k- TSP2; k- TSP3; k-TSP4; k-TSP5; k-TSP1–5; k-TSP1–4; k-TSP1–3; k-TSP1,3,4 |
___
|
miR-626: 83.00 miR-505: 72.00 miR-222: 78.00 k-TSP1: 100.00 k- TSP2: 32.00 k- TSP3: 96.00 k-TSP4: 0.00 k-TSP5:0.00 k-TSP1–5: 96.00 k-TSP1–4: 96.00 k-TSP1–3: 96.00 k-TSP1,3,4: 96.00 |
miR-626: 100.00 miR-505: 97.00 miR-222: 73.00 k-TSP1: 56.00 k- TSP2: 00.00 k- TSP3: 9.00 k-TSP4: 100.00 k-TSP5:20.00 k-TSP1–5: 27.00 k-TSP1–4: 55.00 k-TSP1–3: 55.00 k-TSP1,3,4: 64.00 |
Margis et al (10)10 Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol[Internet]. 2011[cited 2017 May 28];152(3):96-101. Available from: http://www.sciencedirect.com/science/article/pii/S0168165611000678?via%3Dihub
http://www.sciencedirect.com/science/art...
(2011) |
16 |
8 |
8 |
miR-1; miR-22; miR 29a; miR-16-2; miR-26a2; miR-30a |
___
|
___
|
___
|
Molochnikov et al (18)18 Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener[Internet]. 2012[cited 2017 May 28];7:26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424147/pdf/1750-1326-7-26.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2012) |
156 |
92 |
64 |
SKP1A; HSPA8; PSMC4; ALDH1A1; HIP2 |
|
|
|
Park et al (21)21 Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated Levels of a-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease. J Clin Neurol[Internet]. 2011[cited 2017 May 23];7(4):215-22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259496/pdf/jcn-7-215.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2011) |
52 |
23 |
29 |
α- synuclein oligomer;Total α- synuclein |
__
|
__
|
__
|
Parnetti et al (19)19 Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, et al. Differential role of CSF alpha-synuclein species, tau, and A beta 42 in Parkinson's Disease. Frontiers Aging Neurosci[Internet]. 2014[cited 2017 May 28];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978246/pdf/fnagi-06-00053.pdf
https://www.ncbi.nlm.nih.gov/pmc/article...
(2014) |
69 |
44 |
25 |
Aβ142/t-tau ratio; T-α- synuclein; O-α-synuclein; O/t-α-synuclein |
Aβ42/t-tau ratio: 64.00 T-α-syn: 68.00 O-α-syn: 72.00 O/t-α-syn ratio: 78.00 |
Aβ42/t-tau ratio: 82.00 T-α-syn: 59.00 O-α-syn: 89.00 O/t-α-syn ratio: 82.00 |
Aβ42/t-tau ratio:56.00 T-α-syn: 80.00 O-α-syn: 48.00 O/t-α-syn ratio: 64.00 |
Tokuda et al (26)26 Tokuda T, Qureshi M, Ardah M, Varghese S, Shehab S, Kasai T, et al. Detection of elevated levels of a-synuclein oligomers in CSF from patients with Parkinson disease. Neurol[Internet]. 2010[cited 2017 May 28];75(20):1766-72. Available from:http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/665/CN-00772665/frame.html. http://onlinelibrary.wiley.com/o/cochran...
(2010) |
60 |
32 |
28 |
α-synuclein; oligo/total α- synuclein |
α-synuclein: 85.90 oligo/total α- synuclein: 94,80 |
α-synuclein: 75.00 oligo/total α- synuclein: 89.30 |
α-synuclein: 87.50 oligo/total α- synuclein:90.60 |
Vivacqua et (20)20 Vivacqua G, Latorre A, Suppa A, Nardi M, Pietracupa S, Mancinelli R, et al. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. Plos One[Internet]. 2016[cited 2017 May 23];11(3). Available from: http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0151156&type=printable
http://journals.plos.org/plosone/article...
(2016) |
100 |
60 |
40 |
α-synuclein; oligo/total α- synuclein |
__
|
__
|
__
|
Wang et al (15)15 Wang X, Yu S, Li F, Feng T. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. Neurosci Lett[Internet]. 2015[cited 2017 May 23];599:115-9. Available from: http://www.sciencedirect.com/science/article/pii/S0304394015003870?via%3Dihub
http://www.sciencedirect.com/science/art...
(2015) |
202 |
100 |
102 |
α-synuclein; oligo/total α- synuclein |
76.00 |
79.00 |
64.70 |